Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: A potential approach to identify atherosclerotic disease progression

American Heart Journal

Volumn 155, Issue 1, 2008, Pages 56-61

  Gurbel, Paul A ^a   Kreutz, Rolf P ^a   Bliden, Kevin P ^a   DiChiara, Joseph ^a   Tantry, Udaya S ^a  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN C3; C REACTIVE PROTEIN; ENDOTHELIN; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK ASSESSMENT; RISK FACTOR; STABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; FLUOROIMMUNOASSAY; HUMANS; INFLAMMATION MEDIATORS; MALE; METALLOPROTEASES; MIDDLE AGED; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 36849065911     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.08.021     Document Type: Article

References (21)

1. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Zipes D.P., Camm A.J., Borggrefe M., et al. American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation 114 (2006) e385-e484
3. Burke A.P., Kolodgie F.D., Farb A., et al. Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103 (2001) 934-940
4. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41 (2003) 15S-22S
5. Corti R., Fuster V., and Badimon J.J. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 41 (2003) 7S-14S
6. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108 (2003) 1772-1778
7. Loftus I.M., Naylor A.R., Bell P.R., et al. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 89 (2002) 680-694
8. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem J 265 (1990) 621-636
9. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 21 Suppl 1 (2004) II2-II10 [Review]
10. Kereiakes D.J. The emperor's clothes: in search of the vulnerable plaque. Circulation 107 (2003) 2076-2077
11. Kinlay S., and Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol 98 (2006) S2-S8
12. Fukuda D., Shimada K., Tanaka A., et al. Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 97 (2006) 175-180
13. Ferroni P., Basili S., Martini F., et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 51 (2003) 295-300
14. Vignali D.A. Multiplexed particle-based flow cytometric assays. J Immunol Methods 243 (2000) 243-255
15. George J., Patal S., Wexler D., et al. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150 (2005) 484-487
16. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
17. Zeng B., Prasan A., Fung K.C., Solanki V., et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 35 (2005) 331-335
18. Squire I.B., Evans J., Ng L.L., Loftus I.M., and Thompson M.M. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10 (2004) 328-333
19. Barter P.J., and Rye K.A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 259 (2006) 447-454
20. Thompson G.R. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur Heart J 19 Suppl H (1998) H31-H36
21. Kaprio J., Ferrell R.E., Kottke B.A., et al. Effects of polymorphisms in apolipoproteins E, A-IV, and H on quantitative traits related to risk for cardiovascular disease. Arterioscler Thromb 11 (1991) 1330-1348